Vir Biotechnology (VIR) Shares Outstanding (Diluted Average) (2021 - 2026)
Vir Biotechnology recorded quarterly Shares Outstanding (Diluted Average) of $147.4 million in Q1 2026, up 6.38% quarter-over-quarter from $138.5 million in Q4 2025, and up 7.19% year-over-year from $137.5 million in Q1 2025.
Vir Biotechnology's Shares Outstanding (Diluted Average) history runs 6 years deep, the most recent figure standing at $147.4 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 7.19% year-over-year to $147.4 million; the TTM figure through Mar 2026 stood at $147.4 million (up 7.19% YoY), while the FY2025 annual figure was $138.5 million, up 1.67% from the prior year.
- Shares Outstanding (Diluted Average) came in at $147.4 million for Q1 2026 at Vir Biotechnology, up from $138.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $147.4 million in Q1 2026 to a low of $133.6 million in Q1 2023.
- A 5-year average of $136.5 million and a median of $135.7 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
- Across the five-year window, Shares Outstanding (Diluted Average) retreated 0.62% in 2023 and advanced 7.19% in 2026, its largest moves.
- Vir Biotechnology's Shares Outstanding (Diluted Average) stood at $134.8 million in 2022, then fell by 0.5% to $134.1 million in 2023, then grew by 1.58% to $136.2 million in 2024, then advanced by 1.67% to $138.5 million in 2025, then gained by 6.38% to $147.4 million in 2026.
- According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $147.4 million, $138.5 million, and $138.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | 147.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147.36 Mn |
| Dec 31, 2025 | 138.52 Mn |
| Sep 30, 2025 | 138.29 Mn |
| Jun 30, 2025 | 138.45 Mn |
| Mar 31, 2025 | 137.47 Mn |
| Dec 31, 2024 | 136.25 Mn |
| Sep 30, 2024 | 136.06 Mn |
| Jun 30, 2024 | 136.22 Mn |
| Mar 31, 2024 | 135.28 Mn |
| Dec 31, 2023 | 134.13 Mn |
| Sep 30, 2023 | 134.29 Mn |
| Jun 30, 2023 | 133.81 Mn |
| Mar 31, 2023 | 133.55 Mn |
| Dec 31, 2022 | 134.81 Mn |
| Sep 30, 2022 | 134.96 Mn |
| Jun 30, 2022 | 134.64 Mn |
| Dec 31, 2021 | 133.44 Mn |